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Abstract
Targeting transgene expression to specific hematopoietic cell lineages could contribute to the safety of retroviral
vectors in gene therapeutic applications. Chronic granulomatous disease (CGD), a defect of phagocytic cells, can
be managed by gene therapy, using retroviral vectors with targeted expression to myeloid cells. In this context,
we analyzed the myelospecificity of the human miR223 promoter, which is known to be strongly upregulated
during myeloid differentiation, to drive myeloid-restricted expression of p47phox and gp91phox in mouse models
of CGD and in primary patient-derived cells. The miR223 promoter restricted the expression of p47phox,
gp91phox, and green fluorescent protein (GFP) within self-inactivating (SIN) gamma- and lentiviral vectors to
granulocytes and macrophages, with only marginal expression in lymphocytes or hematopoietic stem and
progenitor cells. Furthermore, gene transfer into primary CD34+ cells derived from a p47phox patient followed
by ex vivo differentiation to neutrophils resulted in restoration of Escherichia coli killing activity by miR223
promoter–mediated p47phox expression. These results indicate that the miR223 promoter as an internal promoter
within SIN gene therapy vectors is able to efficiently correct the CGD phenotype with negligible activity in
hematopoietic progenitors, thereby limiting the risk of insertional oncogenesis and development of clonal
dominance.
Introduction
Chronic granulomatous disease (CGD) comprises agroup of immunodeficiencies characterized by mal-
functioning of the phagocytic nicotinamide adenine dinucle-
otide phosphate (NADPH) oxidase, resulting in defective
reactive oxygen species (ROS)–dependent killing of microbes
and consequently leading to recurrent severe bacterial and
fungal infections (Seger, 2008). About 67% of CGD cases result
from mutations within the X-linked CYBB gene encoding the
gp91phox subunit of NADPH oxidase (X-CGD), whereas 16%
result from malfunction of the p47phox subunit (van den Berg
et al., 2009).
The first clinically successful gene therapy (GT) trial for
primary immunodeficiency was reported in 2000 (Cavazzana-
Calvo et al., 2000). Since then, the list of indications for which
GT treatment led to permanent or temporary benefit for
treated patients has been continuously growing (Aiuti et al.,
2002; Mavilio et al., 2006; Morgan et al., 2006; Ott et al., 2006;
Kaplitt et al., 2007; Bainbridge et al., 2008; Cartier et al., 2009;
Boztug et al., 2010; Cavazzana-Calvo et al., 2010; Porter et al.,
2011).
For CGD, the first clinically successful X-CGD GT trial
with proven restoration of ROS production and resolution of
treatment refractory Aspergillus infections was initiated in
2004 in Frankfurt and Zu¨rich. In this study, a gammare-
troviral long terminal repeat (LTR)–driven vector containing
a strong spleen focus-forming virus (SFFV) promoter/
enhancer was used to express gp91phox. However, vector-
mediated transactivation of the EVI1 proto-oncogene in
progenitor cells resulted in clonal dominance progressing to
genetic instability and myelodysplastic syndrome (MDS)
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(Stein et al., 2010). These severe side effects revealed the need
of vector redesign to avoid vector-mediated genotoxic ef-
fects. This could be achieved by using vectors with self-in-
activating (SIN) configuration and cell-type-specific internal
enhancer/promoters, thereby restricting transgene expres-
sion to the deficient cell compartment (i.e., to granulocytes,
monocytes, and macrophages in CGD) and limiting the risk
of proto-oncogene transactivation to cells with limited life
span (reviewed in Toscano et al., 2011). Herewith, we tested
the human miR223 regulatory region, which is highly active
only in myeloid cells, in the context of SIN gamma- and
lentiviral vectors (Fukao et al., 2007) for its expression spec-
ificity, stability over time, and its ability to restore NADPH
oxidase function and mediate bacterial killing.
Materials and Methods
Antibodies and reagents
Anti-human CD14-FITC, anti-human CD206-FITC (clone
19.2), anti-Ly6G-FITC (clone 1A8), anti-Gr1-PE (clone
RB6-8C5), anti-B220-FITC or APC-Cy7 (clone RA3-6B2), anti-
CD3-PE (clone 17A2), anti-CD11b-PE (clone M1/70), anti-
ScaI-PE (clone E13-161.7), mouse Fc-block (clone 2.462), and
Cytofix/Cytoperm Kit were from Beckton Dickinson (Basel,
Switzerland), as was anti-p47phox (clone 1)-APC labeled by
Beckton Dickinson services. Anti-CD11b-PerCP/Cy5.5, APC
or PE-Cy7 (clone M1/70), anti-F4/80-PerCP/Cy5.5 (clone
BM8) and anti-CD117-FITC or APC (clone 2B8), CD45.1-PE
or PE-Cy7 (clone A20), CD45.2-PercP-Cy5.5 (clone 104), and
ScaI-PE-Cy7 (clone D7) were from eBiosciences (Vienna,
Austria). Anti-CD11C-PerCP (clone N418) came from Biole-
gend (Uithoorn, The Netherlands). Anti-DLNGFR-APC,
human and mouse Lineage Cell Depletion Kits, CD14 mi-
crobeads, and Gr1-VioBlue (clone RB6-8C5) were from Mil-
tenyi Biotec GmbH (Bergisch Gladbach, Germany). For
intracellular p47phox staining combined with surface staining,
cells were blocked for 10min at 4C, incubated with surface
staining antibodies for 1 hr, and washed twice followed by
intracellular staining using Cytofix/Cytoperm according to
manufacturer’s description.
Animals
p47phox–/– (B6[Cg]-Ncf1m1J/J) and gp91phox–/– (B6.129S-
Cybbtm1Din/J) mouse husbandry and animal experiments
were carried out in compliance with the local animal pro-
tection law.
Vector construction
The 5¢ regulatory region of the human miRNA223
promoter (782 bp, chrX:65,234,612-65,235,394 GRCh37/hg19
assembly) was amplified from PLB985 gDNA using the
following primers: forward, 5¢-CATATGACTTGTACAGCT
TCACAGGGCTCC (NdeI linker); reverse, 5¢-GGATCCCTGT
CAGTGGAGTGGTGC (BamHI linker). This element was
cloned into lentiviral vectors via the NdeI–BamH1 sites to
replace the MRP8 promoter in the MRP8-gp91-wPRE
(MgpW) vector (Brendel et al., 2011) or the corresponding
GFP-containing MEW vector. Gammaretroviral constructs
were derived from the pSER11M8DN91s vector (M. Grez) by
exchanging the transgene against a synthetic human p47phox
reading frame (Geneart, Regensburg, Germany) and by ex-
changing the internal promoter against promoter candidates
(Supplementary Fig. S1; Supplementary Material available
online at www.liebertonline.com/hgtb). The gammaretroviral
vector encoding SFFV:DLNGFR-2A-p47phox was already de-
scribed (Wohlgensinger et al., 2010). In this construct, the SFFV
promoter was exchanged against the miR223 promoter. Len-
tiviral vectors encoding miR223 p47phox were derived from
the pCCL.CHIM.GP91phox.WPRE (Santilli et al., 2011) by ex-
changing the promoter and the transgene.
Virus production
Virus supernatants were produced in 293T cells upon co-
transfection with pMD2.VSV.G with CMVDR8.91 for lenti-
viral vectors or pUMVS plus the gene transfer vector for
gammaretroviral vectors (Supplementary Fig. S1), using
TransIT-293 transfection reagent (Mirus Bio LLC, Madison,
WI) or calcium phosphate–mediated transfection. Culture
supernatants were collected after 24 and 48 hr, sterile-
filtered, concentrated in Ultracal-100K Centrifugal Filters
(Millipore, Zug, Switzerland) or by ultracentrifugation (2 hr
at 50,000 g at 4C), and stored at - 80C.
Transduction and ex vivo granulocytic differentiation
Murine lineage-negative (Lin–) bone marrow (BM) cells
were isolated from femur and tibias of 6–12-week-old mice
using the Miltenyi lineage cell depletion kit (Miltenyi Biotec
GmbH). The cells were prestimulated for 24 hr in StemSpan
SFEM (StemCell Technologies, Grenoble, France) supple-
mented with mouse stem cell factor (mSCF) (10 ng/ml),
mouse thrombopoietin (mTPO) (20 ng/ml), mouse insulin-
like growth factor 2 (mIGF-2) (20 ng/ml), and human fibro-
blast growth factor 1 (hFGF1) (10 ng/ml) (all from Peprotech,
Hamburg, Germany) at 0.5 · 106 to 1· 106 cells per milliliter.
Transduction was carried out at 20–50 multiplicity of infec-
tions (MOIs) in the presence of protamine sulfate (6 lg/ml)
for 24 hr in 24-well plates. The cells were cultivated for an-
other 24 h before transplantation. For granulocytic differen-
tiation in vitro, the cells were incubated in RetroNectin
(Takara Bio Europe/SAS, Saint-Germain-en-Laye, France)
plates in differentiation medium 1 (RPMI) supplemented
with 20% fetal calf serum (FCS) and 25 ng/ml mouse gran-
ulocyte colony-stimulating factor (mG-CSF) for 3 days up to
2 weeks.
After informed consent, human Lin– cells were isolated
from BM aspirates of a p47phox CGD patient, using the
Lineage Cell Depletion Kit (Miltenyi Biotec GmbH). Lin– BM
cells were expanded for 3 days on 24-well plates coated with
RetroNectin in X-Vivo 10, penicillin/streptomycin, 2mM L-
glutamine, 50 ng/ml human interleukin-3 (hIL-3), 150 ng/ml
human stem cell factor (hSCF), 150 ng/ml human FMS-like
tyrosine kinase 3 (flt3) ligand (hFlt3L), 50 ng/ml human
thrombopoietin (hTPO), and 2% FCS (or 1% bovine serum
albumin). For retroviral transduction, cells were harvested
and centrifuged onto virus preloaded RetroNectin plates.
For ex vivo differentiation, cells were harvested again and
seeded on RPMI (10% FCS, penicillin/streptomycin, 50 ng/ml
hSCF, 10ng/ml human granulocyte colony-stimulating factor
(hG-CSF), 10ng/ml hFLT3L) at day 1. At day 10, cells were
shifted to differentiation medium 2 (differentiation medium 1
without SCF) and incubated for another 10 days, followed by
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FACS sorting using a BD FACSAria Flow Cytometer (Beckton
Dickinson, Basel, Switzerland).
Animal GT
p47phox–/– and gp91phox–/– mice received lethal (9.5Gy or
a split dose of 2· 5.5Gy) irradiation. About 1 · 106 to 2 · 106
gene-modified Lin– BM cells were injected intravenously.
Animals were sacrificed after 7–23 weeks, and blood, spleen,
BM, and peritoneal macrophages were analyzed for trans-
gene expression.
Escherichia coli killing assay
The assay was conducted as described recently (Ott et al.,
2006) with minor modification. Granulocytes were co-
incubated with opsonized E. coli at a ratio of 1:10 for 30min
at 32C. Essentially, neutrophils were incubated with the E.
coli strain ML-35. This particular strain lacks the membrane
transport protein lactose permease and constitutively ex-
presses b-galactosidase (b-Gal). Engulfment of E. coli ML-35
by neutrophils is followed by perforation of the bacterial cell
wall and accessibility to b-Gal, which is subsequently in-
activated by ROS (Hamers et al., 1984). Briefly, 2 · 109 E. coli/
ml were opsonized with 20% (v/v) Octaplas (Octapharma
AG, Lachen, Switzerland) for 5min at 37C. Opsonized E.
coli (final concentration, 0.9 · 108/ml) were added to granu-
locytes (0.9 · 107/ml). At defined time points, granulocytes
were lyzed with 0.05% saponin (Calbiochem, Darmstadt,
Germany) and the samples were incubated with 1mM ortho-
nitrophenyl-bD-galactopyranoside (Sigma-Aldrich, Seelze,
Germany) at 37C for 30min. b-Gal activity was followed by
standard procedures at 420 nm.
Human monocytes/macrophage culture
After informed consent, human monocytes were isolated
using CD14 microbeads. Cryostorage in CryoSto CS10
(StemCell Technologies) resulted in 30% survival upon
thawing. Monocytes were cultured, transduced at a high
MOI, and differentiated to macrophages in RPMI, 10% Oc-
taplas, 2mM L-Gln, 10mM HEPES, 2mM sodium pyruvate,
and M-CSF 100 ng/ml.
Nitroblue tetrazolium test
Macrophages were incubated in 1mg/ml nitroblue tetra-
zolium (NBT; Sigma-Aldrich Chemie GmbH, Buchs, Switzer-
land) in phosphate buffered saline (PBS) containing 200ng/ml
phorbol myristate acetate (PMA) plus 0.5nmol/ml N-Formyl-
Met-Leu-Phe (fMLP) (both from Sigma-Aldrich Chemie GmbH)
for 1hr at 37C and fixed thereafter in PBS and 2% formaldehyde
(Merck [Schweiz] AG, Zug, Switzerland). Photographs were
taken on a Leica DM-IL microscope with a DFC-480 camera
(Leica Microsystems [Schweiz] AG, Heerbrugg, Switzerland).
Dihydrorhodamine 123 assay
About 106 granulocytes in 1ml of Hanks Balanced Salt
Solution (HBSS) with Ca/Mg, 0.5% human albumin, 1000U
catalase, 7.5mM glucose, and antibodies were stimulated
with 200ng PMA and incubated for 5min at 37C. Then, di-
hydrorhodamine 123 (DHR) was added to a final concentra-
tion of 0.435lM, incubated for further 15min at 37C, kept on
ice for 30min, and analyzed using FACS Calibur (Beckton
Dickinson, Basel, Switzerland) or FACS Canto II (Beckton
Dickinson, Heidelberg, Germany).
Results
The miR223 promoter induces transgene expression
upon granulocytic differentiation in vitro
To identify a myeloid-restricted promoter adequate for the
gene therapy of CGD, we analyzed the promoter activity of
a 782-bp DNA fragment derived from the human miR223
promoter within SIN gamma- and lentiviral vector con-
structs, as earlier reports have indicated strong and specific
upregulation of miR223 gene expression during myeloid
differentiation (Fukao et al., 2007; Landgraf et al., 2007;
Johnnidis et al., 2008). We tested the miR223 promoter in
conjunction with the gp91phox and the p47phox subunits of the
phagocytic NADPH oxidase as well as with a DLNGFR-2A-
p47phox fusion construct (Wohlgensinger et al., 2010) (Sup-
plementary Fig. S1).
Initially, we transduced murine Lin– BM cells obtained
from p47phox–/– animals with SIN gammaretroviral vectors
harboring p47phox under control of the miR223 promoter,
and compared this with the specificity of other promoters
derived from myeloid-restricted genes such as cFES (Hey-
demann et al., 2000) and MRP8 (Brendel et al., 2011), or
synthetic promoters like the p40/48 (a 250-nt chimeric pro-
moter consisting of two PU.1 transcription factor binding
sites from the p40 and one PU1 site from the p47 promoter),
or the Sp107 (He et al., 2006) promoters. We used the SFFV
promoter as a benchmark for high expression levels in my-
eloid cells (Supplementary Fig. S1). p47phox expression was
analyzed by FACS upon intracellular p47phox staining 2 days
after transduction in ScaI+ cells as well as in ex vivo differ-
entiated Ly6G+ granulocytes generated thereof (Supple-
mentary Fig. S2A). The mean fluorescence intensity (MFI)
ratio of p47phox expression in differentiated versus undiffer-
entiated cells was used to estimate the induction of transgene
expression upon myeloid differentiation. In this screen, the
miR223 promoter showed the strongest induction of p47phox
expression among the promoters tested (Supplementary Fig.
S2C). In addition, differentiated cells were analyzed for ROS
production in a DHR oxidation assay. We observed a con-
sistent increase in DHR+ granulocytes from cFes, p40/48,
and the miR223-corrected cells, but only the miR223-
corrected population showed a statistically significant increase
of DHR+ cells compared with the mock control (Supple-
mentary Fig. S2B and D). Next, we transduced the human
myelomonocytic cell line X-CGD PLB985 with a lentiviral
SIN vector encoding gp91phox under control of the miR223
promoter (223gpW). Transductions at MOIs of 2 and 0.2 re-
sulted in moderate gp91phox expression levels in 51% and
10% of the cells, respectively. Upon differentiation, the per-
centage of gp91phox-expressing cells increased to 70% and
19%, respectively, in parallel to a significant increase in ex-
pression levels (Fig. 1A). Restoration of ROS production
could be confirmed in 57% of the cells transduced at an MOI
of 2, with DHR MFIs comparable to those of differentiated
wild-type PLB-985 cells (Fig. 1B).
We generated single clones of PLB-985 cells transduced
with a lentiviral vector encoding GFP under control of the
miR223 promoter in order to quantify gene expression
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without variations resulting from antibody staining. The
analysis revealed a good correlation between vector copy
number (VCN) and transgene expression particularly in
differentiated cells (R2 = 0.94), whereas a reduced correlation
was evident in undifferentiated cells (R2 = 0.69) (Fig. 1C). In
53 monoclonal populations, the mean fold induction of GFP
expression upon granulocytic differentiation was 3.5 – 0.88
(Fig. 1D) with a coefficient of variation of only 25.7%.
Moreover, GFP signals in these clones remained stable dur-
ing the total observation period of 4 months (Fig. 1E).
The induction of transgene expression and reconstitution
of NADPH oxidase activity could also be confirmed in
granulocytes obtained upon ex vivo differentiation of trans-
duced murine Lin– gp91phox–/– BM cells. Lentiviral trans-
duction with the vector harboring gp91phox under SFFV
promoter control (SgpW) resulted in similar expression of
gp91phox in hematopoietic progenitors (cKit + ScaI+ ) and
granulocytes (CD11b+ Gr1+ ) (Fig. 2A) with good reconsti-
tution of ROS production in differentiated CD11b+ Gr1+
cells (Fig. 2B). On the other hand, the miR223 promoter
FIG. 1. Performance of miR223 promoter–containing lentiviral vectors in the human myelomonocytic X-CGD cell line
PLB985. (A) FACS analysis of gp91phox expression in undifferentiated (gray) and differentiated (black) X-CGD-PLB985 cells
transduced with 223gpW at MOIs 2 and 0.2 along with nontransduced controls. (B) NADPH oxidase activity in 223gpW-
transduced X-CGD-PLB985 cells assessed by the DHR assay. (C) Correlation of VCN and GFP expression levels in undiffer-
entiated (diamonds) and differentiated (circles) PLB985 clonal cell populations transduced with 223GFP. (D) Fold upregulation
of GFP expression levels during granulocytic differentiation in clonal populations derived from 223GFP-transduced PLB985
cells. Variation of expression levels is given as percentage of coefficient of variation (%CV). (E) Cumulative long-term stability of
GFP expression in 223GFP-transduced PLB985 cells during a 4-month culture period in differentiated and undifferentiated
clonal populations. CGD, chronic granulomatous disease; DHR, dihydrorhodamine 123; GFP, green fluorescent proten; MOI,
multiplicity of infection; NADPH, nicotinamide adenine dinucleotide phosphate; VCN, vector copy number.
FIG. 2. Expression of gp91phox and
NADPH oxidase activity after in vitro culture
of 223gpW-transduced murine X-CGD Lin–
BM cells. (A) 223gpW-transduced murine
Lin– cells were analyzed for gp91phox ex-
pression in stem and progenitor cells (lower
quartiles) and in granulocytes (upper quar-
tiles). (B) Functional reconstitution of
NADPH oxidase activity in X-CGD neutro-
phils mediated by the recombinant expres-
sion of gp91phox as assessed by the DHR assay.
BM, bone marrow; Lin–, lineage-negative.
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(223gpW) mediated weak gp91phox expression in a small
fraction (6%) of the hematopoietic progenitors (cKit+ ScaI+
CD11b– Gr1–), whereas 62% of the CD11b+ Gr1+ cells
showed significant amounts of gp91phox expression, con-
firming induction of miR223 promoter activity upon granu-
locytic differentiation. As in PLB-985 cell–derived granulocytes
(Fig. 1B), miR223-driven gp91phox expression also mediated
high levels of ROS production in granulocytes derived from
transduced primary murine Lin– cells with ROS levels similar
to those observed in granulocytes derived from wild-type
(C57Bl6) or SgpW-transduced X-CGD cells (Fig. 2B).
Collectively, these results strongly indicate an induction of
miR223 promoter activity upon granulocytic differentiation
regardless of transgene identity or the vector system utilized.
The miR223 promoter drives myelo-specific transgene
expression in CGD mouse models in vivo
To characterize the miR223 promoter activity in vivo, we
monitored transgene expression patterns in gp91–/– and
p47–/– mouse models of CGD. After lentiviral transduction
of X-CGD Lin– BM cells with 223gpW and reinfusion into
lethally irradiated recipient mice, gp91phox expression was
analyzed in donor cells up to 23 weeks after transplantation
(Fig. 3A and B; Supplementary Fig. S3). Expression in BM
LSK (Lin– ScaI+ cKit+ ) cells and lymphoid cells (CD3+ or
B220+ ) was almost undetectable, while increasing amounts
of gp91phox were detected during differentiation from pro-
genitor LSK cells (Lin– ScaI– cKit+ ) to monocytes (CD11b+
Gr1–) and to mature granulocytes (CD11b Gr1+ ). Gp91phox
expression in granulocytes led to the reconstitution of
NADPH oxidase activity and ROS production as analyzed
by the DHR assay. The percentages of DHR+ granulocytes
correlated with the percentages of gp91phox expression in
individual animals, and DHR MFIs indicate the production
of significant amounts of ROS at moderate VCNs between
0.7 and 1.5 (Fig. 3B).
In the p47–/– animal model, an miR223 p47phox gamma-
retroviral vector (Supplementary Fig. S1)was used to transduce
syngeneicLin–BMcells, and cell populationswere analyzed for
p47phox expression by intracellular staining 7 weeks after re-
infusion (Fig. 3C). Very lowexpression of p47phoxwas observed
inBMcKit+ ScaI+ or splenicTandBcells (datanot shown), and
expression levels in monocytes remained under the detection
limit. Expression levels in granulocytes were below 11% at an
average of 4%, indicating one copy per cell (Fehse et al., 2004).
AlthoughMFIsofp47phox+ granulocyte signalsweremoderate,
ROS production was restored in all animals (Fig. 3D). The
percentages of DHR+ granulocytes closely correlated with the
percentages of p47phox FACS+ granulocytes (R2= 0.9872). No
adverse events regarding animal health, organ size, and ap-
pearance were observed during these studies. Furthermore,
there was no decline of expression over time, which might in-
dicate the absence of epigenetic silencing.
The miR223 promoter is active
in p47phox-deficient macrophages
As NADPH oxidase function is required in granulocytes
and in macrophages, we tested transgene expression in
peritoneal macrophages of NADPH oxidase–deficient ani-
mals. Lethally irradiated p47phox–/– mice were reconstituted
with Lin– cells transduced with a gammaretroviral vector
encoding the DLNGFR-2A-p47phox fusion construct under
miR223 control, allowing for indirect p47phox detection by
DLNGFR surface staining (Wohlgensinger et al., 2010).
FIG. 3. In vivo expression profile of miR223 promoter–driven gp91phox or p47phox vectors. (A) Lentivirally (223gpW)
transduced Lin– BM cells from gp91phox–/– (CD45.2) mice were transplanted into irradiated SJL mice (CD45.1). Expression of
gp91phox in different donor-derived hematopoietic lineages was determined 23 weeks after transplantation by flow cytom-
etry. Shown in overlay histograms: gray, gp91–X-CGD-PLB985 cells; black, transduced sample. (B) Analysis of the NADPH
oxidase activity in peripheral blood granulocytes derived from the mice shown in (A). (C) Lin– BM cells from p47–/– mice
were gammaretrovirally (miR223 p47phox) transduced and transplanted into congenic recipient mice. Analysis of p47phox
expression and reconstitution of NADPH oxidase activity (D) was performed 8 weeks after transplantation.
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Significant DLNGFR expression was observed in F4/80+
peritoneal macrophages in all treated animals, indicating
miR223 promoter activity in macrophages (Fig. 4A), while
DLNGFR detection signals in splenic T and B cells and blood
dendritic cells were in the range of background staining (Fig.
4B). Next, we analyzed the miR223 promoter activity in
primary human macrophages obtained from blood mono-
cytes of a p47phox-deficient CGD patient. Monocytes were
transduced with lentiviral vectors encoding p47phox under
control of the SFFV or the miR223 promoter and differenti-
ated to macrophages for 7 days, resulting in high levels of
transduction for both vectors (Fig. 4C). ROS production in
primary macrophages was confirmed in an NBT reduction
assay upon PMA/fMLP stimulation (Fig. 4D), clearly indi-
cating miR223 promoter activity in this cell type.
The miR223 promoter–controlled p47 phox expression
restores E. coli killing activity in primary
human granulocytes
To analyze whether miR223 promoter–driven p47phox ex-
pression restores granulocyte anti-microbial activity, we
transduced Lin– BM cells from a p47phox-deficient CGD
patient with the gammaretroviral vector encoding the
DLNGFR-2A-p47phox fusion construct under miR223 or SFFV
transcriptional control followed by granulocytic differentia-
tion ex vivo. DLNGFR surface staining circumvents intracel-
lular staining for p47phox for functional analyses and allows
for the enrichment of gene-modified cells. In differentiated
myeloid cells, gene marking rates of 7%–10% were observed
(Fig. 5A). Stimulation of these cells with either PMA or op-
sonized E. coli resulted in DHR oxidation exclusively in
DLNGFR+ cells, indicating restoration of ROS production in
a p47phox-dependent manner (Fig. 5B). DLNGFR surface
marking of neutrophils, together with CD11b marking of
differentiated granulocytes, was used to FACS-sort mock-
transduced p47phox + (DLNGFR+ ) and p47phox– (DLNGFR–)
granulocytes (all CD11b+ ) derived from cRetro-SIN miR223-
DLNGFR-2A-p47phox and cRetro-SIN SFFV-DLNGFR-2A-
p47phox–transduced cells. Sorted cell populations were then
analyzed in an E. coli killing assay (Ott et al., 2006). In this
assay, an increase in optical density at 420 nm indicates ef-
fective bacterial killing. Both DLNGFR+ populations showed
effective restoration of E. coli killing activity, whereas the
CD11b+/DLNGFR– populations derived from the same
cultures were unable to kill E. coli (Fig. 5C). Thus, antimi-
crobial function was restored in neutrophils expressing
p47phox under control of the miR223 (as well as SFFV) pro-
moter. These data reinforce the potential utility of the
miR223 promoter for high and myeloid-restricted transgene
expression.
Discussion
Transactivation of proliferation-promoting genes as the
primary cause of clonal dominance in gene therapy studies
can potentially be avoided by the use of SIN vectors driving
transgene expression from an internal tissue-specific pro-
moter rather than from strong constitutively active promot-
ers such as the viral LTR (Zychlinski et al., 2008; Modlich
et al., 2009; Montini et al., 2009). Another potential risk arises
from transcriptional read-through, that is, the extension of
viral transcripts through the virus–genome border into the
genomic sequence or splicing of vector transcripts into cel-
lular exons. Both features have contributed to leukemia for-
mation in animal models and clinical studies (Cesana et al.,
2012). For CGD, a myelo-specific promoter driving transgene
expression preferentially in phagocytes could be an option to
FIG. 4. miR223 promoter
activity in macrophages. Lin–
BM cells from p47phox–/– mice
were gammaretrovirally trans-
duced (miR223-DLNGFR-2A-
p47phox) and reinfused into
lethally irradiated p47phox–/–
mice. FACS analysis of (A)
DLNGFR expression in perito-
neal macrophages and (B) T, B,
and dendritic cells after 8
weeks revealed preferential
expression in peritoneal mac-
rophages. (C) Frozen blood
monocytes from a p47phox
CGD patient were taken into
culture overnight and lentivi-
rally (miR223-p47phox) trans-
duced. The cells were kept in
culture for 7 days, followed by
FACS analysis of p47phox ex-
pression in macrophages
(CD206+ CD14+ ). (D) Func-
tional reconstitution of ROS
production was analyzed in
macrophages by nitroblue tet-
razolium assay. ROS, reactive
oxygen species.
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limit transgene expression to short-lived cells, thereby theo-
retically limiting the risks associated with enhancer- or read-
through–mediated activation of proto-oncogenes (Kustikova
et al., 2009; Toscano et al., 2011). The study was motivated by
the results obtained during the long-term follow-up of CGD
patients treated by gene therapy revealing transactivation of
EVI1 as primary cause of clonal dominance with develop-
ment of MDS, and promoter silencing leading to treatment
failure (Stein et al., 2010).
In our study, we evaluated the properties of a DNA
fragment derived from the human miR223 regulatory region
as an internal promoter within SIN retroviral vectors for the
gene therapy of CGD, as the hsa-miR223 gene was reported
to be transcribed nearly exclusively within the hematopoietic
compartment (Landgraf et al., 2007) in a highly myeloid-
specific manner (Fukao et al., 2007; Johnnidis et al., 2008).
In the gp91phox-deficient mouse model, miR223-driven
gp91phox expression resulted in up to 43% gp91phox+ gran-
ulocytes, but the same resulted in only 0.3%–2.2% gp91phox+
early stem and progenitor cells (LSK cells) and in a maxi-
mum of 1.8% positive T and B cells, as assessed by intra-
cellular staining despite mean VCNs of 0.7–1.5 (Fig. 3A). The
lack of gp91phox expression in immature primitive progeni-
tors and B and T cells could be attributed to a detection bias,
as gp91phox is not stable in cells lacking p22phox, the second
component of the cytochrome b558 complex. However,
p22phox is ubiquitously expressed (Chambers et al., 2007) and
gp91phox can be easily detected in LSK cells transduced with
SgpW, a lentiviral vector containing the SFFV enhancer/
promoter element driving gp91phox expression (Fig. 2A)
(Brendel et al., 2011). Similarly, in the p47phox model, miR223-
mediated p47phox expression was weak in BM cKit+/ScaI+
cells and undetectable in T and B cells, while neutrophils
were up to 10.3% p47phox+ . Although the analyses of both
models were performed at different time points, hemato-
poiesis after 7 or more weeks is mainly maintained by
mid- and long-term repopulating multipotent progenitors
(Dykstra et al., 2007; Gerrits et al., 2010). Therefore, lineage-
specific expression is unlikely to originate from the trans-
duction of lineage-restricted progenitors but rather truly
reflects the specificity of the miR223 promoter element. The
expression distribution observed in our experiments resem-
bles the expression pattern of the miR223 gene in mice
( Johnnidis et al., 2008) and humans (Allantaz et al., 2012).
Moreover, our in vitro experiments show that the miR223
promoter can direct gp91phox expression in a VCN-dependent
manner and generates levels of superoxide equivalent to those
observed in differentiated wild-type human myeloid cell lines
and in vitro differentiated murine neutrophils (Figs. 1 and 2).
Myeloid-restricted expression of the miR223 gene has been
attributed to the action of a complex regulatory loop in-
cluding the coordinate binding of CEBP and PU.1 to a region
upstream of the major pri-miR223 transcription start site
(MTSS) and to the binding of C/EBPa and NFI-A to a non-
conserved responsive element 2710 bp downstream of the
MTSS, which corresponds to an intron of the pri-miR223
transcript (Fukao et al., 2007). Although the detailed inter-
play of these two regulatory regions in mediating tissue
specificity has not been clarified, evidence exists that the
intronic regulatory region contributes to miR223 expression
specificity (Fazi et al., 2007). The DNA fragment used in our
studies comprises the MTSS and includes the CEBP and PU.1
FIG. 5. E. coli killing activity of ex vivo differentiated human p47phox–/– granulocytes after gene transfer. Lin– cells from a
p47–/– CGD patient were mock transduced or gammaretrovirally transduced with the self-inactivating SFFV-DLNGFR-2A-
p47phox or the self-inactivating miR223-DLNGFR-2A-p47phox vectors and propagated to granulocytes in liquid cell culture.
(A) Expression of the surrogate marker DLNGFR reflecting p47phox expression in myeloid differentiated (CD11b+ ) and
undifferentiated (CD11b–) cells. (B) Within the CD11b/DLNGFR double-positive populations, 0.1%, 48.7%, and 49.1% re-
sponded by ROS production upon stimulation with phorbol myristate acetate as revealed in the DHR assay (upper panels).
Stimulation with opsonized E. coli (lower panels) resulted in ROS production in 1.3%, 32.1%, and 35.5% of the double-positive
cells. (C) Transduced CD11b+ cells were separated by FACS as indicated by the DLNGFR gates shown in (A) (purity: SFFV,
87%; miR223, 93%). The isolated populations were analyzed for their E. coli killing capacity in a standard killing assay using
the E. coli strain ML35. An increase in optical density at 420 nm indicates bacterial killing activity.
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sites but lacks the binding sites for C/EBPa and NFI-A.
Despite this, a myeloid-restricted expression pattern was
observed in vitro and in vivo.
A recent study characterized a myelo-specific chimeric
promoter generated by the fusion of cathepsin G and c-Fes
minimal 5¢-flanking regions driving gp91phox expression
within a lentiviral SIN vector (Santilli et al., 2011). In com-
parison to this vector, the 223gpW exhibits even lower
leakiness in lymphocytes and more importantly in LSK cells.
One possible explanation for this is the lack of SP1-binding
sites in the miR223 DNA fragment used in this study, which
are present in the chimeric promoter and which may account
for the low levels of gene expression seen in primitive pro-
genitors transduced with SIN vectors containing the chimeric
promoter (Santilli et al., 2011).
Alternatively, miRNA target sequences can also be used to
restrict transgene expression to the desired target population
(Brown et al., 2007). Best example of this is the use of the
miR126 target sequences to detarget expression of an other-
wise toxic gene product (galactocerebrosidase) from HSCs in
the context of gene therapy for globoid cell leukodystrophy
(Gentner et al., 2010).
Although targeting gene expression to myeloid cells in the
context of CGD is a reasonable approach, there is no exper-
imental evidence for a toxic effect of gp91phox expression in
hematopoietic primitive progenitor cells (Grez et al., 2011).
Thus, the relevant issue for CGD vectors is the absolute re-
constitution of superoxide levels, as the analysis of 227 CGD
patients revealed a close correlation between superoxide
production levels and long-term survival (Kuhns et al., 2010).
Unfortunately, a restricted tissue-specific transgene ex-
pression frequently yields weak expression levels. The ques-
tion is whether, despite the high specificity, miR223-mediated
expression levels are sufficient to correct the CGD phenotype.
In our hands, FACS-sorted p47phox+ neutrophils derived
from the BM cells of transduced Lin– p47phox-deficient pa-
tients clearly demonstrated E. coli killing activity ex vivo for
both SFFV- and miR223-containing vectors compared with
the fraction of untransduced neutrophils, indicating that the
level of miR223-mediated p47phox expression in neutrophils
is sufficient to restore the physiological antimicrobial func-
tion of these cells (Fig. 5).
ROS production seems to possess a triggering role for
antimicrobial defense mechanisms, and it is a prerequisite for
NET formation and extracellular killing (Bianchi et al., 2009).
Already, very low amounts of granulocytic ROS production
result in significant changes in membrane potential, K+ ef-
flux, and bacterial killing (Rada et al., 2004). This indicates
that low levels of gp91phox or p47phox expression in CGD
phagocytes could result in significant physiological im-
provement in the clinical status of treated patients. In mice,
already 4%–8% of wild-type granulocytes or 11%–21% gene-
modified neutrophils were sufficient to protect X-CGD mice
against respiratory challenge with Aspergillus fumigatus
conidia, although a significant higher number of gene-
corrected neutrophils was required to improve host defense
of X-CGD animals against Staphylococcus aureus and Bur-
kholderia cepacia (Dinauer et al., 2001; Urban et al., 2009; Bianchi
et al., 2011). We expect our tissue-specific miR223 vectors to
show an improved safety profile compared to vectors with
ubiquitously active promoters, as our highly myelo-specific
expression pattern strongly limits the promoter activity in
stem and progenitor cells and thus may prevent the occur-
rence of side effects while restoring the physiological antimi-
crobial function of gene-corrected neutrophils.
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